vTv Therapeutics (VTVT) Stock Price, News & Analysis

Company Overview

vTv Therapeutics Inc. (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease. These products remain investigational and have not been approved for commercial use unless otherwise authorized by regulators.

vTv Therapeutics was founded in 2001 and is based in High Point, North Carolina. The company’s development programs are supported through clinical research conducted in the United States and other locations, as applicable. Its products are in various stages of clinical development, and the company’s focus and pipeline may change as clinical and regulatory work progresses.

Key Stats

• Today's Range: $23.55 to $24.38
• 50-Day Range: $23.55 to $33.57
• 52-Week Range: $22.45 to $44.00
• Volume: 28,578 shs
• Average Volume: 22,051 shs
• Market Capitalization: $94.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.83
• Consensus Rating: Moderate Buy

vTv Therapeutics Stock Analysis - MarketRank™

vTv Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 261st out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

vTv Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

vTv Therapeutics has a consensus price target of $55.83, representing about 132.3% upside from its current price of $24.03.

Amount of Analyst Coverage

vTv Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for vTv Therapeutics are expected to decrease in the coming year, from ($2.35) to ($4.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of vTv Therapeutics is -22.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of vTv Therapeutics is -22.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

vTv Therapeutics has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.87% of the float of vTv Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

vTv Therapeutics has a short interest ratio ("days to cover") of 5.68.

Change versus previous month

Short interest in vTv Therapeutics has recently decreased by 8.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

vTv Therapeutics does not currently pay a dividend.

Dividend Growth

vTv Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.26

News Sentiment

vTv Therapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for vTv Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

3 people have added vTv Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, vTv Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.99% of the stock of vTv Therapeutics is held by insiders.

Percentage Held by Institutions

17.51% of the stock of vTv Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 11/04/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:VTVT
• CIK: 1641489
• Web: www.vtvtherapeutics.com
• Phone: (336) 841-0300
• Fax: 336-841-0310
• Employees: 26
• Year Founded: 1998

Price Target and Rating

• Average Price Target for vTv Therapeutics: $55.83
• High Price Target: $67.00
• Low Price Target: $42.00
• Potential Upside/Downside: +132.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.97 million
• Net Margins: N/A
• Pretax Margin: -17.38%
• Return on Equity: -6.27%
• Return on Assets: -5.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.48
• Quick Ratio: 12.48

Sales & Book Value

• Annual Sales: $1.02 million
• Price / Sales: 92.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.36 per share
• Price / Book: 1.47

Miscellaneous

• Outstanding Shares: 3,940,000
• Free Float: 3,703,000
• Market Cap: $94.68 million
• Optionable: Not Optionable
• Beta: 0.28